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Abstract Our knowledge of the biology of solid cancer has
greatly progressed during the last few years, and many
excellent reviews dealing with the various aspects of this
biology have appeared. In the present review, we attempt to
bring together these subjects in a general systems biology
narrative. It starts from the roles of what we term entropy of
signaling and noise in the initial oncogenic events, to the
first major transition of tumorigenesis: the independence of
the tumor cell and the switch in its physiology, i.e., from
subservience to the organism to its own independent
Darwinian evolution. The development after independence
involves a constant dynamic reprogramming of the cells and
the emergence of a sort of collective intelligence leading to
invasion and metastasis and seldom to the ultimate acquisi-
tion of immortality through inter-individual infection. At
each step, the probability of success is minimal to infinites-
imal, but the number of cells possibly involved and the time
scale account for the relatively high occurrence of tumori-
genesis and metastasis in multicellular organisms.
Keywords Cancer . Systems biology . Entropy . Noise .
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1 Introduction
Amajor transition in the evolution of life has been the passage
from unicellular to pluricellular organisms. At this stage, each
cell had to transfer its main imperatives (to survive and mul-
tiply) from itself to the organism, i.e., to subordinate them to
those of the whole. The tumor cell accomplishes more or less
completely the reversal of this transfer. In this review, we
propose to analyze this inverse pathway. Transformations at
any level of cell signaling may uncouple to some extent the
tight subordination of a cell to the control of the whole. Over
the long history of the organism, the sequential or simulta-
neous conjunction in cells of many such dysfunctions may
lead in one cell to a transition to complete independence: the
tumor cell. Some of these, the cancer cells, will evolve into an
invasive, metastasizing state and eventually killing inside
invader. From the point of view of these cells, the ultimate
success is the transmission from one organism to another, i.e.,
the immortalization of the tumor by inter-organism infection.
Besides, those who treat cancers often have the impression of
dealing with an organism with its own strategy of survival.
This reminds of the collective behavior of swarms of birds,
fishes, or ants that, through a few simple reflexes, achieve
coherent group behavior: the emergence.
In this assay, we try to present a tentative coherent narrative
framework with known but often unrelated features of solid
cancer evolution generally reviewed separately. In a systems
biology approach, we consider mostly programs, pathways,
and phenotypes rather than individual genes or enzymes used
as examples. Many of the terms used in this literature are
reviewed and defined in Ashworth et al. [1]. We based this
review on important results from recent major journal publi-
cations. We shall consider, from the point of view of the cell,
the causes of oncogenic events, which initiate the programs
leading to the characteristic transition to independence of the
tumor cell, then the evolution of tumors to cancers, metastases,
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and infectious cancers. We shall then discuss the concept of
emergence of swarm-like behaviors in the progression of can-
cer. With regard to causes, we shall mainly consider phenom-
ena more elusive than the direct classical viral or mutational
carcinogens at the origin of a minority of cancers.
2 Causal events
2.1 Propensity for disorder: entropy and its consequences
What is entropy (cf. glossary)? Increasing entropy, the prin-
ciple that, unless provided with new outside energy, any
system will constantly lose usable energy, is a theoretical
formulation for progressive irreversible disorder and ran-
domness in the cells. The concept of entropy (structural
genomic, transcriptomic, network of signal transduction,
etc.) has been repeatedly applied to the characteristics of
cancer tissue or cells: A role in the genesis of cancer was
suggested [2–7], and a causal role was formally proposed in
cancerogenesis [8, 9]. This aspect will be emphasized in this
review. Increased entropy of signaling (or gene interaction
networks) has been well studied as a cancer characteristic:
Network entropy (NE) increases along with cancer pro-
gresses, yielding NEnormal<NEtumor<NEmetastasis [2, 5].
Examples of increasing disorder in the cell will be given in
the next subsection. Increased entropy in cell signaling could
result from any affected level: genetic, DNA damage repair,
epigenetic, transcription control, mRNA editing, miRNA gen-
eration, translation, signaling pathways and cross-signaling,
tissue structure, etc. [8]. In this regard, DNA damage repair,
for example, can be seen as a gatekeeper for increased entropy
of signaling, watching over the order in the DNA sequence.
The cell, as any other living system, degrades over time,
but it repairs itself partially. It transforms by a phenomenon of
graceful or fault-tolerant degradation. The known direct ex-
ogenous causes of cancer, X-ray or UV radiation, mutagen
exposure, inflammation, etc., which can be thought of as
extra-organism sources of disorder, are neutral or deleterious
for part of affected cells and may kill them. But they may also
in very few cells cause the activation of protooncogenes and
inactivation of suppressor genes, leading them on the path to
cancer. Similarly, the major part of signaling degradations and
related mutations will have more neutral and deleterious than
beneficial effects on the cells. Therefore, ultimately, they
mostly lead to aging, senescence, and death by apoptosis or
necrosis. But, among the few survivor cells with positive
effects, only one suffices to initiate a cancer. Entropy of
signaling can, in one cell, favor the appearance of oncogenic
events in this cell, a competitive advantage and/or a greater
probability of further changes, e.g., loss of negative control on
cell proliferation. Further positive changes in these cells will
further increase the competiveness and so on. The tumor cell
will have accumulated enough advantages to become inde-
pendent of normal physiological regulation (Fig. 1). The
diversity of mutation combinations found from one cancer to
another, in any type, is compatible with results of such an
entropy-driven mechanism. The most classical, clinical, and
experimental cancers studied are initiated by one well-defined
oncogenic event such as protooncogene activation or tumor
suppressor gene inactivation, which are also the very frequent
common mutations of many cancers (the drivers in the initial
cells) combined with many rare mutations specific for each
cancer (passengers or enabling) [10]. Thus, study of genetic
defects in human cancers has revealed for each cancer a few
major causative genetic events (driving mutations) and
Fig. 1 The two extreme cases in the carcinogenetic transformation of a
normal cell. Left: stepwise model in which sequential additional genet-
ic events progressively lead to the fully developed, proliferative, and
undifferentiated cancer cell (Vogelstein model). Right: catastrophic
model in which a mitotic catastrophe (chromothripsis) or widespread
mutations around a DNA repair site (kataegis) leads in one step to
death of most cells and in one or a few cells to a cancer cell genotype.
The two models might sequentially happen in the cells
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myriads of minor events, peculiar for each cancer. Whereas
many of the minor events may be considered as mere passen-
ger mutations, some are plural minor contributing events as
illustrated by the many low penetrance polymorphisms linked
to several types of cancer [11]. Thus, carcinogenesis could
also result from a multitude of additional small genetic
changes.
The five to ten driving mutations and hundreds passenger
mutations in one tumor are observed in bulk tumor DNA,
i.e., in the majority of tumor cells, which indicates a clonal
origin [10]. Clonality is demonstrated for most, if perhaps
not all, cancers [12]. This clonality indicates that, out of
many combinations of stochastic events or changes of sig-
naling, only one event combination has initially led to one
tumor. It is not a whole population of cells that progressively
became cancerous but one cell with the right combination of
events. The derived cancer cells will bear the cancer-causing
mutations but also all the random mutations acquired by the
initiating cells before cancer initiation [13].
Cancer may also result from non-progressive acute cau-
salities. Chromothripsis or chromoagenesis, the mitotic ca-
tastrophes caused by mitotic errors leading to widespread
chromosomal rearrangements, induce the death of many
target cells but also leads to aneuploidy, enhanced prolifer-
ation, and carcinogenesis of a few cells [14–16] (Fig. 1). In
this case, it is not the accumulation of such effects but one
major hot event that leads to cancer. Kataegis whereby point
mutations rapidly occur in clusters over hundreds to million
bases plays a similar role [17, 18]. Viral oncogenes, radia-
tion, carcinogenic agents, and inflammation may also lead
to one major tumorigenic event.
Sequential combinations of stepwise and general cata-
strophic genetic events can also occur.
Regardless of the causing mechanism, if the initial
carcinogenetic event bears only on somatic stem cells or
pluripotent cells, it will have to occur in this minor fraction
of the cell population, i.e., the number of potential initiating
cells will be low. Whatever the fraction of the cell popula-
tion involved, the more cells participate in the process, the
greater are the chances that one becomes cancerous. Bigger
breasts have higher cancer occurrence rate. On the other
hand, dwarf mice (with impaired growth due to PTEN
overexpression) are very resistant to cancer [19].
2.2 Examples of increasing entropy in the cell
Agents that hinder DNA replication often cause breaks in
DNA [20, 21]. Transient MAP-2-induced chromosomal insta-
bility leads to lung tumor relapse after oncogene withdrawal
[22]. Cryptic genetic variation, masked by the robustness of
cell phenotype, may also represent an entropy-driven mecha-
nism. It may have, in some circumstances, deleterious effects
but in some others allow rapid evolutionary adaptation [23].
Clonal mosaicism (DNA changes) in subpopulations of cells
of one individual increases with age and is suggested to be a
risk factor for cancer [24, 25].
Aneuploidy resulting from faulty mitosis is a common
cause of increased entropy of signaling in cancer. It is
globally detrimental to cells, slows the rate of cell prolifer-
ation and organism growth [26], but, in a minority of cells,
is associated with cell proliferation and thus frequently with
cancer [27]. This tumorigenic effect is greatly increased
when p53 is inactivated [28]. The most probable explana-
tion for these are differences in gene dosage resulting from
several mechanisms, genetic recombination, and defective
DNA damage repair leading to gain of protooncogenes
expression, loss of tumor suppressor genes, accumulation
of improperly folded proteins, etc. This drives genomic
instability and a mutator phenotype [27, 29].
Transcription-associated mutagenesis and recombination
imply a direct relation between transcription rate and DNA
damage [30]. This may explain in part the strong relation
between division rate and malignity of cancers [31, 32].
Cells could be protected against minor protein structural
defects by heat-shock proteins (HSP) (e.g., HSP90) [33].
Stochastic variations in the HSP expression can allow a mi-
nority of cells with protein defects to demonstrate a phenotype
[34]. Diverse stress conditions lead to HSP transient inhibition
and consequent aneuploidy [35]. Subtle variations in PTEN
concentration and presumably other tumor suppressor genes
predispose to breast tumors in mice [36].
Cancer cells themselves exhibit a less effective shield
against disorder than normal cells, e.g., the disruption of
euchromatin versus heterochromatin replication timing [37]
transcription infidelity [38] and aneuploidy. Even in one
breast cancer cell line, 1 % of the mutations differ from cell
to cell [39]. This will cause a faster evolution of tumors and a
higher rate of cell death. On the other hand, transcription
infidelity will generate mutated proteins that will elicit new
antigenic sites and mild but definite antibody production [40].
Entropy also plays a role in cell biology models. In the
generation of cell lines and in vitro evolution, signaling
pathways which are separate and distinct in physiological
differentiated cells become more and more interconnected in
the derived cells (e.g., PCCl3, WRT, and FRTL5 rat thyroid
cell lines) [41]. The final result of such evolution would be
that almost everything does everything on everything [42]:
an increased network entropy or a promiscuity of signaling
which is the antithesis of tight physiological control.
2.3 Noise as an alternative of entropy or a source to it
Noise represents unavoidable spontaneous stochastic and
reversible fluctuations from one moment to another or from
one cell to another, of any variable (e.g., mRNA, protein,
metabolite level, or structure). Such variations may be minor
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(a few percent) to very significant (whole or none). Noise
functions in multicellular development, differentiation, and
evolution by facilitating transitions [43]. It is expressed as
stochastic bursts of expression, time averaging buffering the
burst, propagation, and eventual amplification of fluctua-
tions. Noise has an important role in genetic circuits and in
the epigenetic landscape [44] by allowing some randomness
in cell behavior [43]. Increased randomness in gene expres-
sion allows cells to better select for conditions best suited
for a given situation [45].
Cell to cell variability and dynamics in the expression of
key transcription factors [46] and at other levels [47] may
allow very different responses of identical cells to changing
conditions. Noisy splicing driving mRNA isoform diversity
in human cells may play a similar role [48].
A consequence of the noise in cell processes is the very
important functional heterogeneity at a given time of similar
cells in the same conditions. For example, thyroid cells
stimulated together with TSH responded, from one cell to
another, with delays of minutes to 2 h by acute thyroid
hormone secretion [49] or the timing of NFKB activation
in 3T3 mammalian cells in culture submitted to the same
stimulus TNF-alpha [50] is very different. Similar heteroge-
neity maintained by heritable epigenetic controls is an im-
portant element in malaria parasites and bacteria bet hedging
[51, 52]. This reversible heterogeneity in bacteria as well as
in human cells may take place in time scales from seconds to
days involving different mechanisms [53, 54]. It is believed
to obey deterministic constrains [55].
Fine-tuning is one aspect of cell physiology that appears
to be opposed to noise. Increasing noise increases the prob-
ability of escaping from existing regulatory constrains; de-
creasing noise decreases the possibilities of adaptation. On
one hand, signaling circuits are robust to mutations and
environmental fluctuations [56]. On the other hand, noise
is extremely difficult to completely suppress [57]. Whereas
noise is reversible and can decrease, entropy, which is
cumulative, always increases. Increase of entropy will lead
to progressive incremental changes, but a fluctuation may
lead to a sudden qualitative change, a binary pattern which
just requires a positive feedback to occur [53]. This could
cause an irreversible change, potentially oncogenic.
Robustness is the capacity of a system to resist changes.
It could be considered as a shield against entropy and noise
[56]. Whatever its involved mechanisms, increased robust-
ness of human cells could account for the requirement of
more mutations to generate cancers in humans than in mice
[58]. One example of the role of noise dampening by neg-
ative feedback as a protection against uncontrolled cell
growth is the activation of p53 after a short mitogenic
stimulus [59] preventing cell cycle entry.
Paradoxically, while robustness characteristics may pro-
tect normal cells against transformation, they may also at the
tumor stage protect the cancer properties or oncogenes (e.g.,
oncogenic Raf stabilized by HSP90) [60].
2.4 Role of miRNA in the control of noise and entropy
A major mechanism of robustness is the redundant control
by miRNA [61, 62]. miRNA controls are partial and
multidimensional; one miRNA has several mRNA targets,
and each mRNA has several controlling miRNA. miRNAs
are fine-tuners of the cell biology (canalization) [63–65].
miRNA can therefore be considered as ideal guardians
against increased entropy: Their moderate and combinatori-
al action is better suited to fine quantitative adjustment than
to qualitative regulation. Their ascribed long half life is also
suited to long-term adjustment and to robustness of a system
[66]. The role of miRNA against increasing entropy is
beautifully illustrated by the very progressive dedifferentia-
tion and loss of tissue structure of mice thyroids in which
Dicer gene, coding for the miRNA generating protein, has
been inactivated (KO) [67]. A role of some miRNA in
limiting the cellular response to E2F activation and thus
preventing replicative stress is another example of such
fine-tuning negative feedback [68]. The general role of
miRNA downregulation in cancer has already been
reviewed [69, 70]. It is remarkable that general defects in
miRNA synthesis progressively lead to transformation and
tumorigenesis [71, 72]. General miRNA concentration de-
creases in cancer, and there are many defects at various steps
of miRNA synthesis in many cancers [73], mostly by epi-
genetic silencing [74]. Most miRNA are downregulated in
tumors, and low levels of miRNA-processing proteins
(Dicer or Drosha) have been associated with the severity
of several cancers [71, 75]. Also in breast tumor cell lines
and breast cancer, a broad set of miRNA are repressed under
estrogen proliferation treatment [76]. This general concept
should not mask the fact that a minority of miRNAs could
be causal agents of tumors [77]. However, loss of Dicer and
the consequent depletion of miRNAs do not preclude tumor
formation by a sarcoma cell line [78].
Although little is known on the subject, entropic alter-
ations of ncRNA could play the same role as those affecting
the miRNAs.
2.5 Relation of entropy to aging
Aging of an organism can be defined as the progressive
decline and deterioration accompanying age. Entropy and
aging are strongly related, as aging is the major consequence
of increasing entropy. Gene network integrity declines with
age in Caenorhabditis elegans [79]. In nucleotide excision
repair disorders, there is a striking correlation between the
degree of repair deficiency, aging, and cancer [80]. Analysis
of 27 datasets of tissue gene expression in aging mice, rats,
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and humans demonstrates over-expression signatures of in-
flammation, immune response, apoptosis, and senescence
[81]. Aging mice have increased chromosomal instability
and cancer [82]. The aging process thus impairs all cells and
increases the probability of cancers in some.
3 Transition to independence (Fig. 2)
The definite transition from a normal cell to a tumor cell
is a fundamental change of philosophy: The cell and its
descendants no longer behave as functional components of
the organism submitted to the physiologically perceived
requirements of the whole [83]; it becomes independent as
a unicellular organism applying to itself and its descendants
the ultimate rules of such an organism: to survive and
multiply [84]. It is a reversal of the fundamental transition
from unicellular to pluricellular organisms. Many of the
genes associated in processes of metazoan multicellularity
are also implicated in cancer [85].
The asociality of tumor cells even goes as far as ingesting
and digesting other tumor cells or even lymphocytes [86,
87]. This transition, as well as the further steps in the
evolution of the tumor [17, 18], may occur stepwise, as in
the Vogelstein model, or at once, e.g., after chromothripsis
[14], kataegis, or in a sequential combination.
When progressive, the evolution of tumor cells involves
several major steps: the independence of growth of the cells
(tumor cells) in a benign tumor, the evolution of the tumor
cell to cancer cell, the process of invasion and epithelial–
mesenchymal transition (EMT), the metastatic process with
its own various steps, and ultimately inter-organism transfer.
Several steps can occur at the same time.
In two landmarks articles synthesizing a huge amount of
information on cancer, Hanahan and Weinberg [84, 88]
outlined the few general properties (hallmarks) that cells
must acquire to become cancerous. In fact, one can interpret
some of these properties as the relief of constrains that
subordinate the normal cells of a pluricellular organism to
the physiological requirements of the whole. Two of these
hallmarks are the prerequisite for the first step of tumori-
genesis, i.e., independence: (1) sustaining proliferation sig-
naling: It involves proliferation as a unicellular organism,
without need of initiation by a physiological growth factor,
and evading of growth suppressors and loss of contact
inhibition [89]; (2) activating invasion involves the relief
of physiological tissue constrains, cell–cell adhesion, polarity,
anoikis, etc. This relief, which may involve genetic or epige-
netic events [90], is also described as field cancerization [91].
It is therefore interesting that the Warburg type of glucose
channeling into non-oxidative metabolism confers resistance
to anoikis [92].
Sustained proliferation and invasion are together suffi-
cient to initiate a tumor. Both are necessary: If repressed,
there is no tumor. For example, cancer cells in a normal
tissue matrix in vitromay not proliferate [93, 94], and cancer
cells inserted in a morula may differentiate in the resulting
organism as perfectly normal cells [95]. When mammary
cells are cultured in a tissue-like environment, isolated cells
expressing one of the most classical oncogenes (ERBB2)
fail to develop and proliferate. Only by moving cells out of
tissue constrains does ERBB2 allow cell transformation.
The negative constrains of pluricellular organisms dominate
Fig. 2 The first phase of
progressive transformation of
an epithelium to an independent
tumor: loss of proliferation
constrains and loss of tissue
constrains in any order
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[96]. Loss of epithelial tissue constrains may follow inacti-
vation of protein(s) involved in tissue organization, e.g., in
gap junctions [97], in tight junctions [98], PAR1 kinase [99],
or in cell substratum adhesion (e.g., by metalloproteases)
[100]. However, loosening of cell compartmentalization,
which is part of the invasion process, is a necessary but
not sufficient carcinogenetic event. Most normal epithelial
cells die when dissociated from the epithelium. The mech-
anisms of loss of epithelial cell organization and of escape
from its lethal consequences are complex and have become
a major research subject [101].
Independent growth induced by cell endogenous onco-
gene or loss of tumor suppressor gene is the second and best
recognized requirement for independent growth. However,
this characteristic is often accompanied by several negative
effects and feedbacks, which must be overcome. Their
mechanisms are multiple and therefore difficult to bypass.
They include: oncogenic induced apoptosis, i.e., suicide
(e.g., Raf-induced apoptosis), oncogenic-induced senes-
cence, DNA damage induced arrest of cell cycle (checkpoint
G1, Gs, G2), or catastrophic mitosis and post-mitotic cell
death. Thus, even at this stage, a high proportion of early
tumors will fizzle out (e.g., in experimental skin tumors)
[102].
The other hallmarks leading to further transition to cancer
may be acquired later in the evolution of the tumor. For
instance, differentiation characteristics are lost progressively
with the aggressiveness of thyroid tumors [103]. In the case
of progressive cancerization, the cumulative probability
over time for a given cell of having accumulated the neces-
sary complementary events and the consequent hallmarks
will increase, along with the growth of cancer incidence
with age [104].
Competition as such is a characteristic of tumor cell
populations, but it also occurs in normal tissue. If indepen-
dence is the first necessary step in tumorigenesis, cell–cell
competition is not sufficient. Competitive interactions be-
tween cells in a compartment or between stem cells in a
niche, already select, better endowed, more competitive
winner cells and their descendants [105, 106]. This repre-
sents a physiological mechanism of selection. Live cell
delamination, followed by cell death, is a physiological
mechanism which counterbalances epithelial growth and
limits tissue overcrowding [107, 108]. Cell competition,
with losers going into apoptosis and winners generating
descendants which replace them, exists in non-tumoral con-
ditions with mechanisms generating supercompetitors (e.g.,
Myc over-expression) and mechanisms protecting for a
while losers from apoptosis (transient Sparc expression
during development in Drosophila) [109]. A p53-
inactivating mutation in bronchial epithelium allowed de-
scendent cells to spread in 70 % of the mucosa [110] without
generating a cancer. Loss of polarity in Drosophila wing
leads to apoptosis and compensatory proliferation [46].
Impairment or the mere heterozygosity of the basolateral
membrane organizer SCRIB is sufficient to initiate prostate
hyperplasia and further biallelic loss [111].
Tissue constrains exerted through polarity, tight, and
adherens junctions restricting cell proliferation are often
mediated by the Hippo pathway [112]. This pathway may
even eliminate deviant tumor cells generated by inactivating
mutations of tumor suppressor genes [113, 114]. The Hippo
and the TOR pathways regulate the control of normal organ
size in opposite direction [112, 115].
4 Evolution from independence to cancer (Fig. 3)
4.1 Mechanisms
Once having acquired its independence, the tumor may
progress or not by successive additional steps to acquire
all the hallmarks of cancers and to develop the competitive-
ness of its cells [116]. It could also acquire all these prop-
erties at once in a few cells after a catastrophic genome
rearrangement (e.g., chromothripsis, kataegis …). We shall
mainly consider the progressive model.
“Tumors evolve by a reiterative process of clonal expan-
sion, genetic diversification and clonal selection within the
adaptive landscapes of tissue ecosystems. The dynamics are
complex with highly variable patterns of genetic diversity
and resulting multiclonal architecture” [117–120]. The pro-
cess is favored by the mutator phenotype of cancer cells
[121], with the mutation rate increasing in more advanced
stages [18].
The role of the DNA damage response as an anticancer
barrier in early tumorigenesis suggests that new genomic
instability is an early phenomenon after independence [122]
and contributes to evolution. Among the genetic events, some
like those affecting genes of the splicing machinery are fre-
quent andmay influence entire programs [123]. Themutations
may also involve recurrent hemizygous, sometimes extensive,
deletions [124]. The reprogramming of characteristics is there-
fore largely a result of the reprogramming of the genome itself
with the emergence of new genomic systems [125]. Clonal
evolution of tumors (e.g., in leukemia) in response to treat-
ment has been demonstrated by whole genome sequencing
[126].
This evolution also involves epigenetic and possibly
lysogenic-like and transcriptional control mechanisms [40,
127, 128]. In colon cancers, epigenetic events are far more
frequent than genetic events [129], and in lung cancer, they
may account for the regression of most differentiation genes
[130]. Transcriptional networks, which are able to maintain
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cellular identity, certainly also have the capacity to play a
major role in cancer cell identity [131].
The Darwinian selection will eliminate many less compet-
itive clones [132]. The cells will lose physiological character-
istics (i.e., differentiation) that are unnecessary for their
survival and reproduction, if not all characteristics of the cell
of origin, some of which being used in the new context. The
end result is a great diversity and heterogeneity [133, 134].
Examples are the greatly increased mRNA heterogeneity in
cancers [38] and the great diversity of single-nucleotide mu-
tations from cell to cell in a cancer [135–137]. Cancerization is
not a linear process either in space or in time.
Just the fact that cancer cells proliferate, vary epigeneti-
cally, and mutate allows them to discover myriads strategies
to escape attacks by anticancer drugs [138, 139]. Noise
increases the adaptability in the cancer cell population.
Similarly, the faster increasing entropy of cancer cells,
e.g., in chromatin replication timing [140], favors the ap-
pearance of new mutations, allowing some cells to resist
therapies based on existing oncogenic mutations [141]. For
example, treatment of B-Raf mutated melanoma selects cells
with Ras mutations which will short-circuit the inhibition
and re-establish the activation of MAP kinases in the tumor
and also in normal cells, thus generating new skin carcino-
ma [142]. Treatment of cells of an osteosarcoma cell line by
nutlin which blocks p53 degradation leads to somatic
inactivating mutation of p53 and selects for p53 mutated
cells [143]. Inhibition or lack of telomerase activity in
human cancers leads to alternative lengthening of telomeres
mechanisms [144]. An analogy between the evolution of
drug resistance in bacterial communities and malignant tis-
sue has been suggested [145].
On the other hand, some mutations or epigenetic controls
while not being beneficial or detrimental per se might in-
troduce a new vulnerability to treatment [146, 147].
Moreover, the process of adaptation by mutation is not
necessarily infinite, e.g., in bacteria diminishing returns of
epistasis among beneficial mutations decelerates adaptation
[148] and lead to an equilibrium of maximal efficiency.
The pervasive increasing entropy in tumor cell evolution
will, as in the normal cells, generate far more deleterious than
favorable genetic and epigenetic events. This will lead to the
development of much more uncompetitive than competitive
cells. Tubiana had demonstrated this [149]: Only 10 to 20 %
divisions in breast cancer cells contribute to tumor growth.
The less competitive cells may divide a few times but not
infinitely, redifferentiate, and become senescent, quiescent, or
even die. The other, more competitive cells may correspond to
the so-called cancer stem cells postulated by the cancer stem
cell theory that we called cancer stem–tumor-propagating
cells [132]. These cells, defined by different sets of properties
depending on the systems and the authors, need not be a fixed
distinct population of cells, but rather one extreme phenotype
in an evolving population [132, 150, 151].
Thus, the same increase in entropy that generated initially
the tumor-initiating cell will impair many cells during the
evolution of the tumor but allows new adaptations to arise in
a minority.
Due to the stochastic nature of genetic events and their
relation with cell divisions it is not astonishing that the best
Fig. 3 Schematic view of steps
in tumor evolution. From one
normal cell, to dominance of
this cell, independent benign
tumor, invasive tumor, cancer,
and metastasis. The width of the
arrows suggests the relative
importance of the relations
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prognostic markers of tumor evolution are the Ki67 prolif-
erative index and tumor size [31, 32]. The more cell di-
visions, the more cells involved, and the more mutations, a
fraction of which will contribute in the affected cells to
positive tumor cell evolution.
4.2 Features of the evolution
Besides the properties acquired in the first transition to
independence, mobility, autonomy, and escape of tissue
constrains, what are the properties progressively acquired
by tumor cells in their evolution to cancer cells, the hall-
marks of cancer [84]?
These properties include the capacity to react indepen-
dently to the environment (e.g., O2 availability, signals from
other cells), loss of differentiation, the search for O2 and
substrates; movement, propagation, and exploration behav-
ior; proliferation whenever, wherever it is possible; escape
harmful conditions and environment; escape immune reac-
tions; escape of metabolic control; and escape of apoptosis.
These correspond to the imperatives of the cancer cell
progression and invasion. At the step of invasion, the tumor
has acquired the full set of cancer properties, and it is a
required step for metastasis. Tumor cells may migrate in
bulk as clusters, strands, or sheets (collective migration) or
individually. In the latter case, they may, after EMT, either
proceed through the extracellular matrix by hydrolyzing and
remodeling it or may swim around it as an amoeba [152].
These patterns are reversible depending on the context (e.g.,
extracellular matrix organization).
The newly acquired properties are not independent; they
all reflect the new character of the cell: its cancerishness. A
nice illustration of this is the finding that all proposed
specific gene expression signatures of breast cancers are
related and therefore give redundant prognostic results
[32]. The programs and their resulting hallmarks represent
a complex interrelated dynamic network in which some
hallmarks themselves drive new programs. In this regard,
the Warburg reorganization of cell metabolism in cancer is
both a consequence and a cause of the cancer process itself
[153–155]. The Warburg effect confers resistance to anoikis
[92]. The invasion programs imply a close and reciprocal
interrelation with the extracellular matrix and the various
micro-environmental cancer and non-cancer cells. They
present a great variety. The dynamic interrelations of the
hallmarks are also illustrated by the many mechanisms of
immune escape. Cancer vaccination drives Nanog-
dependent evolution of tumor cells toward an immune-
resistant and stem-like phenotype [156]. Hypoxia induces
escape from innate immunity through HIF and Adam10
[157] and promotes tolerance via Treg cells [158]. Lactate
as such stimulates migration, radioresistance, and immune
escape [159]. A large part of the program of embryonic stem
cells taken over by cancer cells is the prevention of
differentiation.
The evolution of the independent tumor to cancer will
involve the acquisition, progressively (evolution) or abrupt-
ly (e.g., after chromothripsis), of all those properties, not
necessarily in a given sequence. At any step, the progression
of a tumor clone may stop, but this will have little general
effects at stages when many clones coexist. Also, higher
saturation density is increasingly permissive for expression
of the neoplastic transformation [94].
This evolution will involve the acquisition of all these
properties leading to tumor growth, the required angiogen-
esis, invasion, and ultimately metastasis. Exaggerated an-
giogenesis will increase but also restrain tumor access and
become a pathological process per se [160]. The evolution
will result from branched genetic evolution within the tumor
[134] as well as even more frequent epigenetic changes
[161–163].
For this evolution, the cells will transiently or permanent-
ly appropriate programs that improve their competitiveness
and growth. The over-expression by human cancers of
genes that are specific to a variety of normal human tissues
[164] may reflect this adaptation or/and the increasing en-
tropy of cancer cells. Most often, cancer cells do not invent
new programs; they co-opt or highjack available programs
expressed in some circumstances by certain cells such as,
for invasion, the wound program [165]; for growth, the
regrowth program of amputated liver; for adaptation, to flux
the program of blood cells; for escape of differentiation
constrains, programs of embryonic stem cells, etc. One other
example is the appropriation of leukocytic trafficking and
leukocyte attraction mechanisms for invasion and metastasis
[166]. To provide itself with the necessary building blocks
for proliferation, the cancer cell activates permanently a
temporary program of the normal cell cycle [167], thus
generating a permanent Warburg effect [168].
Versatility in the use of such programs confers to the cell a
nimbleness that reminds of the embryonic cells. For instance,
cMyc oncogene when expressed induces proliferation but
suppresses cancer metastasis [169], i.e., negative and positive
roles played by over-expressing the same protein.
In a given cancer, there is complementarity, a synergy
between amplified and mutated genes in eliciting programs
[170]. Many cells need an active PI3K pathway to grow, and
when they have no activating mutation of the pathway, they
over-express IGF1 receptors [162]. When the pathway is
inhibited by therapy, recurrences make use of a Met or cMyc
amplification [171]. Similarly, the widespread potential of
cancers to adapt to treatment may involve the redundancy of
growth factor-regulated signaling cascade [172], heterodimeric
activations [173], emergence of new mutations [174], etc.
The respective use of all these programs varies for dif-
ferent cancers and for one cancer at different times and
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locations, depending on the existing conditions and the cells
accessible programs [175]. For instance, telomere dysfunc-
tion in the absence of telomerase generates very disadvan-
tageous genomic instability but is often corrected by re-
expression of telomerase [126]. EMT transition can sup-
press major attributes of human epithelial tumor-initiating
cells [176]. Plasticity, reciprocity, and evolution are the
major characteristics of these processes [175, 177].
The evolution of cancer toward independent and maxi-
mal growth, and loss of differentiation characteristics leads
to a convergence of phenotypes between cancers of same
type with very different genotypes [178] and even between
different cancer types [178, 179], especially for the most
dedifferentiated cancers. However, the programs used will
often still reflect characteristics of the cell of origin, which
are useful for their progression. For instance, transcription
factor TTF1 (also called NKX2.1), which is used and nec-
essary in thyroid and lung normal cells proliferation is still
used and necessary for pulmonary and thyroid cancer cell
lines growth [180].
Not all cancers use all available programs. For instance,
basocellular skin carcinoma or brain tumors may not express
EMT program nor develop metastasis. Also, not all the
cancer cells in a cancer express the same programs, nor do
they necessarily express them all the time, e.g., EMT is
induced in some peripheral carcinoma cells and is reversible
after metastasis [181].
A step of the evolutionary process is the development
of the cancer independently of its initial cause, e.g., the
skin tumor in response to a mutagenic then progression
treatment, which develops independently of the causal
oncogenic events thereafter. By contrast, a hyperplastic
tumor may develop with a hormonal treatment or with
the expression of an oncogene, both of which recede
when the stimulus is stopped [182]. In the first case,
the tumor cells have acquired an independent property,
but, in the other, did not. Oncogenic addiction, the nec-
essary activity of one oncogene for tumor progression
characterizes this latter type. Because of its mechanistic
simplicity and economy, it is very efficient but offers
simple therapeutic targets. The inverse, oncogenic inde-
pendence may arise following treatment (e.g., by relief of
a negative feedback on EGFR in Raf-induced melanoma)
[183, 184]. It explains some resistances to single target
treatments. Non-oncogene addiction may also occur, for
example, to heat-shock factors that compensate for pro-
tein denaturing stress resulting from the increasing entro-
py of cancer cells [124, 185].
The classical scenario of tumor progression to cancer de-
scribed so far should not obscure the fact that many tumors do
not progress or even regress. This is a well-recognized possible
fate of benign tumors such as hemangiomas, lymphangiomas,
gliomas, etc. Thyroid microcarcinomas, with all the
characteristic of classical papillary carcinomas (e.g., B Raf
mutations, RET-PTC rearrangements), are found in up to
30 % systematic autopsies. Most never evolve [186].
Similarly, naevi may be considered as dormant quiescent mel-
anoma [187]. There are many dormant breast carcinomas
[188], prostatic intraepithelial neoplasia [189]. Mechanisms
of these evolutions are poorly reversible senescence [189]
which may result from the uncorrected oncogenic stimulus
itself [189] or the control by T cell infiltration [190].
5 Metastasis program
The generation of metastases is a third step in the evolution
of a cancer. It is most important and lethal since it is
responsible of 90 % of cancer deaths worldwide.
As shown by mutation patterns of tumors and metastases,
metastases can be generated early from the bulk of the tumor
as well as late in its evolution from some cells in the tumor
[191]. A lot of arguments in favor of each concept show that
both are valid. However, the rarity in the primary tumor of
clonal genetic events found in metastasis suggests that only
rare cells in this tumor have the ability to metastasize [192].
The genealogy of metastases shows that some are early,
some are late, and some are even metastases of metastases
[193]. Moreover, there are metastases of undetected cancers
[194]. Thus, the metastasis program can be independent of
other cancer cell programs.
The steps involved in the metastasis process have been
analyzed [195, 196]. They include invasion, individualiza-
tion or not of the cells by EMT, migration toward capillaries,
intravasation, survival in circulation, extravasation, seeding,
and growth as metastasis. EMT which ultimately individu-
alizes the cells, which then acquire a mesenchymal type,
implies the loss of cell–cell adhesion and cadherins and a
switch of the cytoskeleton proteins from cytokeratins to
vimentin [93, 152]. It is a major determinant of metastasis
[197].
Each metastasis step implies different capacities and pro-
grams and a certain frequency of failures. After EMT, ex-
travasation of the cells is certainly facilitated by their
attraction to oxygen and by the large but tortuous and leaky
vascularization of the tumor [198]. Moreover, cancer cells,
by decreasing stiffness and increasing cytoskeletal remodel-
ing of endothelial cells, break down the endothelial barrier
[199]. Survival in the circulation certainly requires the hall-
mark characteristic of escape from anoikis, the apoptosis of
cells that lost cell contact.
According to Valastyan [195], once in circulation, sur-
vival, extravasation, and seeding are very efficient. Eighty
percent of intravenously implanted carcinoma cells succeed
in extravasation. These steps do not even require malignan-
cy of the cells as normal mammary cells succeed to achieve
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seeding if not growth [200]. On the other hand, the attrition
rate for metastases is evaluated at 99.98 %, i.e., a suc-
cess rate of 2/104 [201]. As it is difficult to imagine a
significant evolution in the few hours or days between
intravasation and seeding, either the necessary capacities
for metastatic development are stochastically available in
a fraction of the intravasating cells or they are acquired
in some cells later after seeding. The major limiting
factor is the tissue environment, i.e., in part, the compo-
sition of extracellular matrix, the niche [202]. Also, the
cancer cell may exploit for its implantation surface pro-
teins expressed by chance, e.g., claudin-2-expressing
breast cancer cells functioning as unspecialized adhesion
molecules to bind breast cancer cells to hepatocytes
[203]. Additionally, primary tumor-associated stromal
cells can also be seeded in secondary sites and potentiate
the metastases formation [204].
It is easy to explain metastases of peripheral organs in the
lung where venous blood from the tumor will have to pass,
or metastases of visceral organs in the liver where most of
their venous blood passes. It is more difficult to conceive
how groups of cells of a diameter from 10 to 30 μm can
escape the filters represented by the capillaries of lung and
liver. However, there are venous shunts in the lung, which
allow less than 1 % of the circulating blood to bypass lung
capillaries. The necessity of intravenous shunts to bypass
liver and lung would imply a great attrition rate at this level.
On the other hand, isolated cancer cells, the present favored
origin of metastases [205], could flow through the capil-
laries, as the leukocytes do. In fact, such cells also hijack
other leukocyte programs, e.g., for extravasation [166].
Choice of the metastatic site, the organ-specific metastat-
ic tropism, will be conditioned by the environment (e.g.,
cytokines, etc.) and by the adaptation of the seeded cells to
their environment. Those breast cancer cells that succeed to
colonize the lung are those which produce tenascin as a
metastatic niche complement [202].
The stochastic character of the transition of cancer cells
to metastasis is illustrated by the nice relation between size
of tumor and number of metastases [149].
The ultimate step in the evolution to total independence
of cancer cells is the success of some cancers to transfer
from one organism to another, as parasites do: by infection
like Tasmanian devils transmissible tumors, which in their
path to total independence have even managed to acquire
new mitochondria from one transitory host [206]. This can-
cer has now evolved in several subclones sufficiently dif-
ferent to evade immunity against one of them [207]. Canine
transmissible venereal tumor is another example [208, 209].
Other examples of interorganism transfer are the cases of
maternal transmission to offspring [210], fetus to fetus
transmission [211], and transmission with organ transplants
[212].
6 Cooperation, “swarm intelligence,” and “emergence”
in cancer
What is emergence (cf. glossary)? To the clinician who treats
it, cancer often appears as an intelligent enemy, displaying
what is known as swarm intelligence. Swarm intelligence
refers to the collective behaviors of a decentralized self-
organized system composed of single individuals interacting
locally by few signals. It is also called collective intelligence
or said to display an emergent property. The interactions
between the single entities are stochastic. The equilibrium
reached by the whole population is dynamic. In that context,
emergence is the generation of swarm intelligence in a collec-
tion of such individuals. It must result from the acquisition by
Darwinian selection of the appropriate reflexes by the whole
population. It is therefore a biological concept [213, 214].
Common examples are flocks of migrating birds, of fishes,
ant colonies, soil microbes [166], and perhaps packs of cars at
the beginning of vacation. In emergence, the different units of
an entity display teleonomic, i.e., apparently purposeful be-
havior [215].
Normal cells display cooperation. Bacteria use few sig-
nals and stereotyped responses to cooperate once their den-
sity is sufficient (quorum sensing), to develop swarming
behavior, luminescence, and other cooperative behaviors
[216]. Animal gene regulatory networks by themselves gen-
erate emerging properties [217]. The major process of inva-
sion, the collective tumor cell invasion, involves concepts of
cell–cell cooperation and collective behavior [205] pro-
grams appropriated from embryological development [214].
The complex interplay between genetically distinct
populations within a cancer has already been discussed with
examples of commensalism (i.e., positive interaction where
one clone benefits the others) and mutualism (cooperation
between populations) [1].
Hypoxia and angiogenesis represent one striking exam-
ple of “intelligent cooperation.” The response to hypoxia is
a remarkable general response of the tumor cells to a dele-
terious condition, with cells moving toward oxygen and
vessels, becoming more malignant, etc. In fact, tumor ves-
sels’ therapeutic targeting promotes adaptations in cancer
that result in increased malignancy [218].
Hypoxia and HIF1α induce aggressive growth, invasion,
angiogenesis, and metastasis in xenografts of human cancers
[219], zebrafish tumors [220], and pancreatic cancer cells
[221]. The activation of HIF leads to the induction of
SNAIL transcription factors conferring EMT and stem cell
properties [222] and of transcription factors such as OCT4
conferring stemness properties [223], telomerase, and
multidrug transporters. Hypoxia and HIF also promote
VEGF secretion and angiogenesis and activate an invasive
program by upregulatingMet tyrosine kinase [224]. Similarly,
lactate levels predict likelihood of metastasis and tumor
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recurrence in human cervical cancers [225]. The shift to
glycolysis from glucose oxidation (Warburg effect) protects
cells from anoikis after detachment [92]. Some glioblastoma
cells even generate endothelial cells and vessels themselves
which irrigate the tumor [21, 226]. Thus, hypoxia and HIF
induction, early consequences of the process of tumorigenesis,
are major drivers of this process [227].
Cancer invasion potential and resistance to therapy are
interconnected properties, more or less linked programs that
may induce each other [228].
Another example of cooperative collective behavior is
illustrated by the tumoral control of the microenvironment.
In the invasion process, there is a reciprocal reprogramming
of both tumor cells and the surrounding tissue [177]. For
example, the breast cancer-associated fibroblasts which in-
duce EMT and chemoresistance [229], stromal fibroblasts
surrounding cancer cells, may stretch out in parallel net-
works letting cancer cells move along them [230]. Tumors
may secrete PDGF-BB to stimulate stromal cells to produce
erythropoietin which induces angiogenesis and red cell gen-
eration, i.e., which improves their oxygen supply [231].
They also recruit mesenchymal stem cells which stimulate
growth, metastasis, and resistance to cisplatin [232] and
which supply them with cysteine, allowing them to synthe-
size the necessary glutathione [233]. On the other hand, of
course cancer cells compete with normal cells. A role of
secretory miRNA of tumoral cells has been proposed in this
regard [234].
In experimental models, cooperation may also involve
different tumor cells with complementary mutations (e.g.,
Ras V12 and SCRIB-mutations [192]. Even senescent can-
cer cells may harness wound healing responses to support
the other cancer cells [235].
Inflammation is another cooperative phenomenon. Its
role is illustrated by the remarkable slowing down of tumor
progression by aspirin treatment [236]. Recognition of
tumor-specific antigens by lymphocytes leads to cancer
immunoediting, loss of tumor antigen expression or presen-
tation in some cells that will then selectively outgrow the
others [237], secretion of immunosuppressive cytokines,
lymphocytic inhibitory enzymes (e.g., indoleamine 2,3
dioxygenase), or recruitment of immunosuppressive Treg
cells [238]. Tumor acid pH inhibits T cell immunity [239].
Clearance of apoptotic cells, very frequent in cancers, re-
sults in the production of anti-inflammatory cytokines [240].
On the other hand, acquisition by melanoma and colon
cancer cells of chemokine receptors (CXCl3, CXCR1,
CCR7), which in lymphocytes attract the cells to lymph
nodes, will lead these cancer cells to lymph node invasion
[241].
Cooperation may also be observed as response to therapy.
During cancer radiotherapy, tumor cells dying from apopto-
sis stimulate growth and repopulation of the tumor [242].
Danger signals produced by irradiated tissues also comprise
pro-angiogenic molecules, thus protecting the vasculature
[243].
An even more daring but still to be substantiated theory
would have the cancer-cell-secreting factors that would mo-
bilize bone marrow-derived cells to pre-metastatic sites
[244]. Another hypothesis is the transmission of neoplastic
properties from transformed to normal human stem cells
[245].
All these examples of cell cooperation could represent
true emergence, i.e., a collective behavior resulting from
reflexes of signaling acquired by a Darwinian selection.
The evolution from drug-sensitive to insensitive cells
does not fall into the emergence category as it reflects
rescuing mutations in a few cells that take over and regen-
erate a whole population [246].
7 Efficiency of the cancer process
Although collectively, cancer cells are deadly, at the level of
the individual cells, the carcinogenetic process is remark-
ably inefficient. At each step of the cascade, the frequency
of events deleterious to the cell outnumbers the frequency of
positive evolutionary events, but these generate the progres-
sion. In mammary cancers, up to 90 % of the cells are
doomed [149]. The cancer stem-tumor-propagating cells
concept, with only a fraction of the cancer cells being
competitive, implies the same conclusion [132].
At each step of the cascade, especially in the early steps,
the lack of a supplementary event may stop the process in its
track. This explains the high frequency of benign or static
tumors (e.g., cancer in situ). At each step of the cascade,
tumors can even regress if they have not achieved immor-
tality (e.g., hemangioma). However, at the end of the evo-
lutionary process, one cell is sufficient to generate a
xenotransplanted mammary tumor [247].
A gross estimate of cell number at different stages of
thyroid cancer evolution gives an appreciation of the effi-
ciency of cancerization from the point of view of the cell.
One thyroid (3×109 cells) with 7 % annual renewal [248]
over 30 years generates one or two nodules in 50 % of the
female population, (probability 1/1010 per cell) of which
5 % are malignant (probability 5×10−12 per cell). At another
level, a cancer of 1 g (±5×108 cells) releasing in the blood
50.000 cells per day or 2×107 cells per year, generating five
metastases in 5 years, represents a probability of 5×10−8
metastasis per released cancer cell. Even for a release of
500 cells/day, the probability would be 1×10−6. Finally,
only two cells in history, the Tasmanian devil and the canine
transmissible venereal tumor cancer cell, managed to pass
regularly from organism to organism, i.e., to become infec-
tious and thus immortal.
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8 Conclusion
Besides the minority of cancers arising from direct exoge-
nous causes such as radiation, carcinogens, viruses, or in-
flammation, the majority of cancers do not originate from
single obvious events but rather from multiple chance
events in the normal life of our 3×1013 cells. We link these
events to the increasing entropy in the cell physiology and to
the noise in our cell metabolism, which may initiate the
process in some cells. This can lead to the major reverse
biological transition from cells in pluricellular organisms,
which obey constrains of the whole, to unicellular organ-
isms, which independently strive to survive and multiply.
After this transition to independence, the same causal mech-
anisms coupled to a Darwinian selection will cause the
evolution to progression, invasion, metastasis, and in a few
cases immortality as infectious agents. At the cellular level,
this evolution will make use in a dynamic and reversible
manner of the various existing normal cells programs. It will
involve adaptive cell survival strategies and even apparent
cooperation between cancer and normal cells from the mi-
croenvironment. This will be accompanied by a profound
genomic remodeling. Finally, the cancer process, when con-
sidered from the cell point of view, is extremely inefficient
at many stages: in the initiation as well as during the pro-
gression, when only rare mutations are viable and improve
cell competiveness. Due the high number of cells possibly
involved at the level of the organism and its lifespan, the
probability of cancer and metastasis remains high.
The concept of an evolution of tumor cells to a diverse
population of more and more competitive cancer cells through
a process of rare consecutive stochastic genetic or epigenetic
events suggests several therapeutic considerations.
First, whatever the lesions involved, the removal of a
large part of the cell population in which the event takes
place, i.e., the surgical approach, will greatly restrict the
population in which further oncogenic events will occur. It
will therefore remain fundamental.
Second, wherever the tumor has arrived in its evolution,
the avoidance of further oncogenic events may delay or stop
this oncogenic evolution and is therefore useful. It is well
known that 5 years after abstention from smoking, the
probability for lung cancer is brought back to a much lower
level [249].
Third, whatever the stage of a cancer, a temporary re-
prieve may be helpful. In a differentiated thyroid carcinoma
of a 60-year-old patient, one or two reprieves of 5 to 10 years
would allow an almost normal lifespan.
Fourth, the great heterogeneity of tumor cell populations
in a tumor, even with a single similar initial oncogenic event
and the increase in signaling entropy which multiplies re-
dundant signaling, suggest the interest of broad simulta-
neous multi-target therapies [127, 250–252].
Pending questions
& Do cancers arise from somatic stem cells, pluripotent
cells, or/and from any cell?
& In the sequential multistep model of carcinogenesis
(Vogelstein), may the order of oncogenic events vary?
& To what extent are micropapillary carcinomas of the
thyroid, or naevi, permanently dormant cancers or newly
generated tumors on the way to extinction?
& Are the cells in dormant tumors, in dormant parts of the
tumor or in dormant metastases quiescent, senescent,
and permanently differentiated?
& What are the roles of ncRNAs and alternative splicing?
& In real in vivo human cancers, which cells express which
programs (e.g., EMT, proliferation, somatic cell charac-
teristics, etc.)? Are these programs always or randomly
expressed, exclusive of each other?
Glossary
Chromothripsis Mitotic catastrophe caused by
mitotic errors leading to
widespread chromosomal
rearrangements [14].
Emergence The appearance in a system of
swarm intelligence, i.e., a
collective behavior of a self-
organized system without central-
ized control, composed of single
entities interacting locally by a
few signals (e.g., fish swarm). The
tumor is composed of single tu-
moral and stromal cells that are
our entities. They interact with
signals that depend on their envi-
ronment, and they undergo selec-
tive pressure. They seem to
display intelligent behavior
through the emergence of a sort of
collective intelligence. Intelli-
gence is not a human-restricted
notion (e.g., artificial intelli-
gence). Think of bots in video
games that are, by design, intel-
ligent entities, understanding
their environment and reacting
to changes in it to maximize
chances of success. Remember
that, before being rendered as
human-looking pixels on
screens, bots are lines of code
on hard drives. An intelligent
tumor or cell has no conscious-
ness but adapts through selective
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pressure to its environment by
reacting to its changes.
Entropy Theoretical formulation for
progressive irreversible disorder
and randomness: It is a notion
used in diverse fields that requires
prior definition. The second
principle of thermodynamics
stipulates that entropy of an
isolated system always increases.
In familiar terms, unless provided
with new outside energy, any
system constantly loses usable
energy. For example, we might
imagine a machine, e.g., an old
car, which is machined to support
a certain type of action. Whether it
is left in a garage or used on a
daily basis, a shift may be
observable with time from its
original behavior. The degradation
causing this behavioral shift in
machines can be linked to
dissipation processes or increased
macroscopic entropy and is used
in modeling machine reliability.
But entropy is also a statistical
thermodynamics measure of
disorder at a microscopic level and
is, so to speak, a generalization of
the macroscopic thermodynamic
measurement. It is not necessarily
linked to loss of usable energy but
rather to the number of possible
configurations of the components
of the system. The cell is our
system. Its internal initial order
and environment determine its
behavior. In the same
environment, while losing this
order (e.g., by acquiring
mutations), the cell may behave
differently. This is because of
increasing entropies of gene
interaction networks (entropy of
signaling) that have actually been
measured and compared in
different publications (see main
text). Consequently, increased
entropy is used as a metaphor of
progressive irreversible and
random loss of initial order in the
cell; it is strongly linked to aging
and will shape cell behavior.
Graceful degradation
or fault-tolerance
Property of a system (the cell) that
enables the system to function
properly (survive) after failure of
one of its component (disorder-
driven degradation at any level in
the cell).
Kataegis Sudden appearance of clusters of
point mutations in a chromosome
after DNA damage and repair [17,
18].
Noise Unavoidable spontaneous
stochastic fluctuations in space
and time of a biological variable.
Robustness The resistance of a system to noise
and disorganization; its capacity to
behave normally despite new
defects or disorders.
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